eripheral arterial obstructive disease (PAOD), a pathologic process of atherosclerosis of the arteries of the lower limbs, is defined as an obstructive arterial disease that reduces arterial blood flow during exercise or, in advanced stages, at rest. Current estimates show that it affects approximately 8-12 million people in the United States; and this number will undoubtedly grow as the geriatric patient population increases. 1 The natural history of patients with PAOD is also affected by coexistent coronary artery disease. 2, 3 The presence of PAOD is asymptomatic in most patients and detected by abnormal results of non-invasive tests. Symptomatic patients usually present with classic intermittent claudication, atypical pain, or critical limb ischemia (CLI). However, patients can present with CLI initially without having experienced previous symptoms. 4, 5 Among patients with intermittent claudication, 30% will progress to resting pain and CLI, and approximately 18% will require lower extremity revascularization over a 10-year period. 6, 7 As the use of the most effective pharmacologic agents results in only a modest improvement in claudication, 8-10 participation in a structured program of regular exercise, 8-12 control of associated medical diseases or risk factors, surgical revascularization, and percutaneous transluminal angioplasty (PTA) 13 are currently considered the most beneficial management options. Unfortunately, the risks of perioperative death, long-term graft failure, and contraindications to or limitations of PTA restrict the use of active intervention for patients with claudication, especially for those with infrapopliteal and diffuse lesions.
A few reports have suggested that intermittent pneumatic compression (IPC) therapy is an effective and safe limb salvage therapy for patients with PAOD. 14-18 However, the patients included in these previous studies were almost always those with accompanying superficial femoral artery occlusion, aortoiliac vessels free of hemodynamically significant disease, a patent popliteal artery with minimal atherosclerotic lesions,
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stable intermittent claudication, and only unilateral intermittent claudication at baseline. Data are lacking for patients with infrapopliteal diffuse or multiple segmental lesions. Moreover, no definitive data are available regarding improvement in quality of life (QOL) among patients infrapopliteal PAOD treated with IPC. Therefore, we conducted this study to fill these gaps in our understanding of the role of IPC.
Methods
Patients with a clinical diagnosis of PAOD who visited our clinic volunteered to participate in this prospective study. PAOD was diagnosed by physical examination and confirmed by an angiogram, duplex ultrasonography, and ankle-brachial blood pressure index (ABPI). All patients received treatment with cilostazol before enrolling in the study. The diseased arterial criteria for study entry were: (1) ABPI <0.9, (2) culprit vessel having infrapopliteal involvement, and (3) diffuse or multiple segmented lesion morphology. The clinical criteria for study entry were symptomatic peripheral artery disease with severe intermittent claudication (Rutherford stage 3: study group 11, control group 4), chronic CLI with pain while the patient was at rest (Rutherford stage 4: study group 5, control group 2), or chronic CLI with ischemic ulcers (Rutherford stage 5: study group 7, control group 2). A total of 31 patients with infrapopliteal diffuse or multiple segmental lesions and symptomatic CLI, with no surgical or endovascular options for revascularization, were enrolled in the study. Informed consent was given by all patients, and the study was approved by the local ethics committee. Based on receipt of IPC therapy, patients were allocated to a study (n=23, IPC therapy positive) or control (n=8, IPC therapy negative) group. IPC of the foot and calf was performed while the patient was seated (Figure) . The ArtAssist device (model AA-1000, ACI Medical, San Marcos, CA, USA) which has a frequency of 3 impulses/min, an impulse rise time of 1 s and a delay of 4 s for calf compression, was used. The inflation pressure was 120-140 mmHg. The deflation pressure was 0 mmHg, with a deflation time of 15 s. IPC was performed bilaterally in cases of bilateral claudication. Patients in the study group received IPC therapy for 3 h daily for 3 months.
Standard blood tests, including fasting serum glucose level, lipid profile, and proinflammatory and inflammatory markers, were performed. All blood samples were drawn at the same time of the day (between 8 and 10 am). The blood samples were separated and frozen at -80°C until analysis.
Assessment of the ABPI was performed by well-trained cardiologists following a standard protocol as previously described. Patients were examined in the supine position after at least 5 min of rest. Systolic blood pressure was measured in both arms and in the right and left posterior tibial and dorsalis pedis arteries of each leg. A Doppler stethoscope (8 MHz) and standard blood pressure cuff connected to a random zero manometer were used to detect the arterial flow. The resting ABPI was the ratio of ankle systolic blood pressure (the average of the pressure recorded in posterior and dorsalis pedis arteries) to the higher of the left or right brachial pressure. The lower of the ABPI values obtained for the 2 legs was used as the gauge of disease in the analysis. Patients were excluded if they had undergone a previous vascular surgical procedure on the aortoiliac vessels because of ischemic legs (regardless of whether they had ABPI <0.9 before the surgical procedure), or with ABPI ≥1.5 in both legs at baseline, because previous analyses showed this represents a falsely high level derived from calcified non-compressible vessels in the legs.
Vascular properties were evaluated by determining the brachial/ankle pulse wave velocity, ratio of mitral inflow velocity to early diastolic velocity in the annulus derived by tissue Doppler imaging (E/Et), and intima-medial thickness.
Waist circumference was measured at a point midway between the lowest rib and the iliac crest with the patient standing. A value greater than 90 cm in males and 80 cm in females was considered high. The hip circumference of the patients was also measured in the standing position, from the plane of both major femoral trochanters. The waist-to-hip ratio was calculated by dividing the waist circumference by the hip circumference, and a value ≥0.9 in males and ≥0.8 in females were considered high. Body mass index was calculated by dividing the body weight in kilograms by the height in meters squared (kg/m 2 ). Subjects with a body mass index ≥27 kg/m 2 were identified as high.
Self-assessment of QOL was evaluated with the SF-36 scoring system (translated into Taiwanese) by every patient at the beginning and the end of IPC therapy. The SF-36 scoring system contains 36 items in 8 domains: physical functioning (PF; extent to which health limits physical activities such as self-care, walking, climbing stairs, bending, lifting, and moderate and vigorous activities); physical role functioning (RP; extent to which physical health interferes with work or other daily activities, including accomplishing less than desired, limitation in the kind of activities, and had difficulty); emotional role functioning (RE; extent to which emotional problems interfere with work or other daily activities, including decreased time spent, accomplishing less than desired, and not working as carefully as usual); social functioning (SF; extent to which physical health or emotional problems interfere with normal social activities); bodily pain (BP; intensity of pain and effect of pain on normal work, both inside and outside the house); mental health (MH; general MH, including depression, anxiety, behavioral-emotional control, and general positive affect); vitality (level of energy); general health perceptions (GH; personal evaluations of health, including current health, Figure. Intermittent pneumatic compression therapy technique to compress the foot, ankle and calf of patients with peripheral arterial obstructive disease. IPC for Claudication QOL health outlook, and resistance to illness). 19, 20 Each domain contained 2-10 items. Moreover, the score for each domain was transformed to a scale from 0 to 100. A higher score indicated higher functioning and better health and QOL.
A 6-min walking test was performed for all patients at the beginning and end of IPC therapy. Initial and absolute claudication distances (ACDs) were recorded: the distance at which pain first occurred was the initial claudication distance (ICD) and the maximum distance terminated by pain was the ACD. The 6-min walking test was performed according to the statement guidelines for the American Thoracic Society. 21 We measured the transcutaneous oxygen tension (TcPO2) levels with an electrode attached for 20 min to the skin of the distal end of the ischemic leg (usually recorded at the sites of the popliteal, posterior, or dorsalis pedis arteries) and to the skin of the chest as a control. 22 All the patients underwent the QOL, 6-min walking test and TcPO2 assessments in the beginning and end of the study.
The Statistical Package for Social Sciences (SPSS) 14.0 for Windows was used for statistical analysis, and all the values were expressed in terms of mean ± SE and frequency. Student's t-test was applied to compare the differences in QOL, walking distance/duration, and TcPO2 between the beginning and end of study. A P value <0.05 was considered significant.
Results
A total of 31 patients with infrapopliteal diffuse or multiple segmental lesions and intermittent claudication with a mean age of 68.8±2.6 years enrolled in the study. The demographic characteristics of patients are summarized in Table 1 . The prevalence of each of diabetes mellitus (78.3% vs. 87.5%), hypertension (78.3% vs. 75%), metabolic syndrome (56.5% vs. 62.5%), and hypo-high-density lipoprotein cholesterolemia (56.5% vs. 75%) was high, whereas that of other forms of dyslipidemia and obesity was not. The progenitor cell, proinflammatory, and inflammatory markers among the patients are shown in Table 2 . High levels of D-dimer, homocysteine, lactate, and high-sensitivity C-reactive protein were found. Otherwise, relatively low levels of circulating progenitor cells (CD34 + ) and endothelial progenitor cells (CD34 + KDR + ) were present in these patients. Rather high prevalence of left ventricular diastolic dysfunction, arterial stiffness, and increased carotid intima-media thickness were demonstrated echocardiographically in these patients (Table 3) . However, there were no differences between the study and control groups for these baseline characteristics, inflammatory biomarkers and echocardiographic parameters.
In Table 4) .
The ABPI values showed no significant differences in both groups during the 3-month study period (0.72±0.03 vs. 0.71± 0.02, P=0.288 in the study group; 0.75±0.05 vs. 0.73±0.32, P=0.561 in the control group). In comparison with the 6-min walking duration, ICD and ACD, the study group showed significant improvement after IPC therapy (2.1±0.3 vs. 4.1± 0.4, P<0.001; 21.3±2.9 vs. 52.3±9.9, P=0.004; 56.3±9.5 vs. 109.0±12.2, P<0.001). However, no differences were found in the control group ( Table 5 ).
In the study group, the TcPO2 at the different sites of the ischemic limb showed no differences above the knee (103.1± 7.1 vs. 110.8±7.1, P=0.231) or below the knee (94.0±6.6 vs. 105.0±7.5, P=0.089). However, the TcPO2 in the distal end of the ischemic limb increased significantly (65.0±8.8 vs. 92.8± 6.9, P<0.001) after IPC therapy. In the control group, the TcPO2 showed no significant improvement in above-knee, belowknee, and distal end levels (86.6±14.3 vs. 82.5±8.6, P=0.529; 89.2±10.8 vs. 74.2±9.3, P=0.034; 41.7±11.5 vs. 39.9±9.6, P=0.563) at the beginning and end of study ( Table 5) .
Discussion
Previous reports have documented that the application of IPC to the lower limbs of patients with PAOD may produce a significant increase in the native arterial calf inflow. 23-25 Resting popliteal arterial volume flow in seated patients with claudication was found to increase 3.2±1.6-fold with the application of IPC 26 and by 51-84% with intermittent foot compression. 14, 27 Arterial flow increased substantially in legs with resting pain when intermittent foot and calf compressions were exerted simultaneously. 28 In addition to verifying the acute effect of IPC on volume flow, its long-term therapeutic potential in patients with intermittent claudication (Fontaine class 2) has also been investigated. 17 According to Delis et al, 16 IPC used at home for 4.5 months increased claudication distance by over 100%, and associated increases in resting ABPI by 18%, post-exercise ABPI by 110%, and arterial calf inflow by 36% suggest improved collateral circulation. Maximum benefit seems to occur in the initial 3 months, and are maintained for 1 year. These findings indicate the significant effects of this mechanical method for PAOD patients. 17 Furthermore, Montori et al reported that patients with CLI and nonhealing wounds at high risk for amputation can achieve complete wound healing and limb preservation with IPC therapy. 23 However, the patients included in those studies had accompanying superficial femoral artery occlusion, single stenotic lesions in the aortofemoral segment, and a patent popliteal artery with minimal atherosclerotic lesions at baseline. There are limited data reported for the application of IPC to patients with PAOD who have infrapopliteal diffuse and multiple segmental lesions.
The value of stratification of treatment modalities for specific lesions has been validated in several studies that have documented outcomes of endovascular intervention stratified by the TransAtlantic inter-Societal Consensus (TASC) Working Group classification. [29] [30] [31] According that classification, however, there is a lack of the data on PTA for distal lower limb arteries such as the peroneal, posterior tibial, and dorsalis pedis arteries. Furthermore, it notes insufficient information for PTA in diffuse lesions throughout previous studies. In fact, there are fewer single stenotic lesions and above-knee lesions (fitting in with the TASC classification) in the clinical setting. In contrast, diffuse, multiple, and below-knee lesions accompanying intermittent claudication and CLI are most common lesion patterns in real-world patients. Furthermore, old age, preexisting nephropathy, and comorbid cardiovascular or cerebrovascular diseases restrict invasive therapy for complex lesions. In fact, we often chose a supportive or quiescent treatment strategy for this patient group. In our present study, increased TcPO2 tension at the end of IPC therapy provided objective data supporting an improvement in the degree of cutaneous ischemia in the patients. Therefore, IPC therapy may be an adjunct, or sometimes almost the only and last therapeutic option, for patients with PAOD who have infrapopliteal diffuse and multisegmented lesions.
In addition, our report illustrated the efficacy of IPC for CLI with complex lesions among patients at high risk of amputation. In this study, after 3 months of IPC therapy, walking duration increased by 95%; and the ICD and ACD increased by 146% and 94%, respectively. These results show that IPC therapy is not only effective for aortofemoral lesions, as presented in previous reports, but also benefits patients with infrapopliteal diffuse and multisegmented lesions.
The effect on the patient's QOL of significantly disabling claudication that results in an inability to perform normal work or other activities that are important to the patient should be considered. Furthermore, the potential for substantial differences between the patient's and the physician's assessments of QOL need to be taken into account. 32 Numerous studies have shown that successful revascularization can improve the patient's QOL and may reduce cardiovascular events because the patient remains mobile. 33, 34 In spite of the increasing life expectancy, QOL has become one of the main concerns in daily practice for these disabled patients. Maintenance of good QOL and reduction of symptomatic clinical events are important goals both for patients with CLI and clinicians. In our experience, some patients even choose QOL over survival. Among the instruments for evaluation of generic disease, SF-36 is one of the most frequently used in studies of health. In the present study, the scores for PF, RP, RE, BP, GH and MH increased significantly after IPC therapy, which illustrates that IPC therapy not only improves the ability to exercise but also affects QOL for patients with infrapopliteal complex PAOD.
A multicenter, randomized clinical trial is required to determine the effect of IPC among patients with infrapopliteal complex lesions, the appropriate patients for this mechanical intervention, and the long-term results and role of IPC therapy. However, the patients in our study benefited from this therapy despite their poor prognoses. IPC may be a useful tool for such patients with complex PAOD until a more advanced treatment is developed.
Study Limitations
Regarding ethnic considerations as well as patients' willingness for treatment or not, a study design of blindness and randomization of patients was impossible because treatment was via clinical procedures instead of pharmaceuticals and placebo. However, any potential selection bias was eliminated because all pretested baseline data were non-significant statistically between the 2 groups of patients. Besides, blindness of the surveyors was followed such that none of the technicians knew whether patients were being treated with a clinical procedure. However, larger-scale and more detailed studies are needed to confirm our conclusions.
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Conclusions
In summary, although many treatment options, such as bypass surgery, PTA, and mechanical methods, are available for patients with PAOD who have aortofemoral and single lesions with intact popliteal arteries, there are few data supporting the application of IPC for patients with CLI or intermittent claudication who have infrapopliteal, diffuse, and multisegmented lesions. Our study suggests that IPC effectively increases exercise ability and tolerance, TcPO2 tension, and QOL among such patients.
